J. Moul

发表

HEPSIN inhibits cell growth/invasion in prostate cancer cells.

V. Srikantan, Michael Valladares, J. Rhim, 2002, Cancer research.

Comparison of prostate biopsy protocols using 3D computer simulation

J. Moul, S. Mun, J. Zeng, 1998, Proceedings Pacific Medical Technology Symposium-PACMEDTek. Transcending Time, Distance and Structural Barriers (Cat. No.98EX211).

Guideline for the management of clinically localized prostate cancer: 2007 update.

A. D'Amico, C. Tangen, D. Eton, 2007, The Journal of urology.

The role of imaging studies and molecular markers for selecting candidates for radical prostatectomy.

J. Moul, C. Kane, S. Malkowicz, 2001, The Urologic clinics of North America.

p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy.

F. Mostofi, J. Moul, S. Srivastava, 1999, The Journal of urology.

Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility.

D. Chan, I. Thompson, A. Partin, 2005, Clinical chemistry.

PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer.

M. Augustus, F. Mostofi, V. Srikantan, 2000, Proceedings of the National Academy of Sciences of the United States of America.

Delay in diagnosis and survival in testicular cancer: impact of effective therapy and changes during 18 years.

J. Moul, R. Dodge, D. Paulson, 1990, The Journal of urology.

The role of magnetic resonance imaging (MRI) in focal therapy for prostate cancer: recommendations from a consensus panel

Hessel Wijkstra, John Kurhanewicz, Osamu Ukimura, 2014, BJU international.

Racial differences in tumor volume and prostate specific antigen among radical prostatectomy patients.

Wei Zhang, F. Mostofi, J. Moul, 1999, The Journal of urology.

Prostate cancer in men of African origin

J. Moul, Kathleen F. McGinley, K. Tay, 2016, Nature Reviews Urology.

African American Men With Low-Risk Prostate Cancer Are Candidates for Active Surveillance: The Will-Rogers Effect?

J. Moul, Robert Qi, 2017, American journal of men's health.

Absent ras gene mutations in human adrenal cortical neoplasms and pheochromocytomas.

J. Bishoff, J. Moul, E. Chang, 1993, The Journal of urology.

Detection of RAS mutations in archival testicular germ cell tumors by polymerase chain reaction and oligonucleotide hybridization

J. Moul, E. Chang, S. Theune, 1992, Genes, chromosomes & cancer.

Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy.

J W Moul, F. Mostofi, J. Moul, 1996, The Journal of urology.

Cathepsin D and epidermal growth factor receptor immunohistochemistry does not predict recurrence of prostate cancer in patients undergoing radical prostatectomy.

J. Moul, J. Mohler, S. Maygarden, 1996, The Journal of urology.

p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy.

J. Moul, J. Bauer, I. Sesterhenn, 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

Maspin expression profile in human prostate cancer (CaP) and in vitro induction of Maspin expression by androgen ablation.

Wei Zhang, J. Moul, S. Srivastava, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Blinded evaluation of reverse transcriptase-polymerase chain reaction prostate-specific antigen peripheral blood assay for molecular staging of prostate cancer.

J. Moul, S. Srivastava, R. Connelly, 1999, Urology.

Proteomics in prostate cancer

J. Moul, S. Srivastava, L. Bañez, 2005, Current opinion in urology.

Applications of neural networks in urologic oncology.

J W Moul, J. Moul, T H Douglas, 1998, Seminars in urologic oncology.

Medical technologies for the diagnosis of prostate cancer

J. Moul, N. Fitzsimons, Leon L Sun, 2007, Expert review of medical devices.

Future Directions in Prostate Cancer Diagnosis

J. Moul, L. Bañez, N. Fitzsimons, 2008 .

Editorial comment on: Development of a new method for monitoring prostate-specific antigen changes in men with localised prostate cancer: a comparison of observational cohorts.

J. Moul, Leon L Sun, P. Tang, 2010, European urology.

TWENTY‐FIVE YEAR EVOLUTION OF MEDICAL HORMONAL THERAPY FOR PROSTATE CANCER

J. Moul, 2009, BJU international.

Biochemical recurrence after definitive prostate cancer therapy. Part II: Treatment strategies for biochemical recurrence of prostate cancer*

J. Moul, J. Ward, 2005, Current opinion in urology.

Age-specific reference ranges for serum prostate-specific antigen in black men.

J. Moul, W. Mccarthy, D. Mcleod, 1996, The New England journal of medicine.

Impact of socioeconomic status and race on clinical parameters of patients undergoing radical prostatectomy in an equal access health care system.

J. Moul, C. Amling, C. Kane, 2000, Urology.

Testicular cancer in blacks: A multicenter experience

T. J. Wilkinson, J. Moul, B. Colls, 1994, Cancer.

Rising PSA in nonmetastatic prostate cancer.

J. Moul, S. Freedland, L. Bañez, 2007, Oncology.

Focusing on testosterone.

J. Moul, R. Dreicer, 2011, Urology.

Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer

J. Moul, 2009, Cancer.

Rising PSA in nonmetastatic prostate cancer.

J. Moul, S. Freedland, L. Bañez, 2007, Oncology.

Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy.

Timothy F. Donahue, J. Moul, C. Amling, 2004, The Journal of urology.

Combination hormonal therapy: a reassessment within advanced prostate cancer

J. Moul, G. Chodak, 2004, Prostate Cancer and Prostatic Diseases.

Variables in predicting survival based on treating "PSA-only" relapse.

J. Moul, 2003, Urologic oncology.

Biochemical recurrence of prostate cancer.

J. Moul, 2003, Current problems in cancer.

Evolution of therapeutic approaches with luteinizing hormone-releasing hormone agonists in 2003.

J. Moul, J. Fowler, 2003, Urology.

PSA Recurrence of Prostate Cancer : Published on Cancer Network

J. Moul, S. Freedland, J. Ward, 2017 .

Postoperative radiotherapy of the prostate for patients undergoing radical prostatectomy with positive margins, seminal vesicle involvement and/or penetration through the capsule.

J. Moul, D. Paulson, P. Walther, 1990, The Journal of urology.

Supplement Article Traditional Approaches to Androgen Deprivation Therapy

J. Moul, M. Roach, R. Dreicer, 2011 .

Traditional approaches to androgen deprivation therapy.

J. Moul, M. Roach, R. Dreicer, 2011, Urology.

Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy.

Jason C. Massengill, Timothy F. Donahue, J. Moul, 2003, The Journal of urology.

Original Articles PRETREATMENT TOTAL TESTOSTERONE LEVEL PREDICTS PATHOLOGICAL STAGE IN PATIENTS WITH LOCALIZED PROSTATE CANCER TREATED WITH RADICAL PROSTATECTOMY

Jason C. Massengill, J. Moul, C. Amling, 2003 .

Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers.

J. Moul, S. Srivastava, I. Sesterhenn, 1994, Cancer research.

Factors associated with blood loss during radical prostatectomy for localized prostate cancer in the prostate-specific antigen (PSA)-era: an overview of the Department of Defense (DOD) Center for Prostate Disease Research (CPDR) national database.

J. Moul, C. Amling, W. Sexton, 2003, Urologic oncology.

Epidemiology of radical prostatectomy for localized prostate cancer in the era of prostate-specific antigen: an overview of the Department of Defense Center for Prostate Disease Research national database.

J. Moul, C. Amling, W. Sexton, 2002, Surgery.

Detection of circulating prostate specific antigen expressing prostatic cells in the bone marrow of radical prostatectomy patients by sensitive reverse transcriptase polymerase chain reaction.

J. Moul, S. Srivastava, R. Connelly, 1999, The Journal of urology.

The role of the p53 tumor suppressor gene in prostate cancer: a possible biomarker?

J. Moul, S. Srivastava, J. Bauer, 1996, Urology.

Assessment of circulating tumor cells (CTCs) in prostate cancer patients with low‐volume tumors

J. Moul, S. Srivastava, I. Sesterhenn, 2010, Pathology international.

Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer

J. Moul, J. Madden, V. Mouraviev, 2007, Cancer.

Prostate cancer laterality does not predict prostate-specific antigen recurrence after radical prostatectomy.

J. Moul, J. Madden, V. Mouraviev, 2007, Urology.

Negative pressure devices in the explanted penile prosthesis population.

J. Moul, D. Mcleod, 1989, The Journal of urology.

Expression during Prostate Cancer Progression Exhibits Cell Growth Inhibitory Function and Decreased PMEPA 1 , an Androgen-regulated NEDD 4-binding Protein

Wei Zhang, J. Moul, S. Srivastava, 2003 .

PMEPA1, an androgen-regulated NEDD4-binding protein, exhibits cell growth inhibitory function and decreased expression during prostate cancer progression.

Wei Zhang, J. Moul, S. Srivastava, 2003, Cancer research.

Effect of race on biochemical disease-free outcome in patients with prostate cancer treated with definitive radiation therapy in an equal-access health care system: radiation oncology report of the Department of Defense Center for Prostate Disease Research.

J. Moul, C. Amling, C. Kane, 2002, Radiology.

Reply from Authors re: Seth A. Strope, Gerald L. Andriole. Prostate-Specific Antigen–Based Risk Assessment in Younger Men. Eur Urol 2012;61:8–9

W. Catalona, J. Moul, F. Schröder, 2012 .

Platinum Priority – Collaborative Review – Prostate Cancer Baseline Prostate-specific Antigen Testing at a Young Age Hemodilution and Psa Concentration among Men with Prostate Psa Values Using Sequence Variants Associated with Psa Levels. Sci Goteborg Randomised Population-based Prostate-cancer Scre

W. Catalona, J. Moul, H. Carter, 2022 .

The economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan data.

J. Moul, D. Penson, C. Evans, 2004, The Journal of urology.

Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy.

E. Crawford, J. Moul, A. Barqawi, 2003, Urology.

Evaluation and Active Treatment versus Active Surveillance of Localized Prostate Cancer in Renal Transplant Patients in the Era of Low and Very Low Risk Prostate Cancer.

J. Moul, T. Polascik, C. Robertson, 2019, The Journal of urology.

Race/ethnicity and the receipt of watchful waiting for the initial management of prostate cancer

V. Shavers, J. Moul, C. Klabunde, 2004, Journal of General Internal Medicine.

Prevalence and correlates of non-tissue prostate cancer diagnosis in the United States.

A. Jemal, J. Moul, Helmneh M Sineshaw, 2019, Journal of geriatric oncology.

Screening for prostate cancer in african americans

J. Moul, 2000, Current urology reports.

Cancer-Specific M ortality A fter S urgery o r R adiation f or Patients W ith C linically L ocalized P rostate C ancer M anaged During t he P rostate-Specifi c A ntigen E ra

A. D'Amico, D. Lubeck, P. Carroll, 2003 .

Prostate biopsy quantitative histology as a staging and prognostic factor.

J. Moul, 2002, The Journal of urology.

External validation of the SEARCH model for predicting aggressive recurrence after radical prostatectomy: results from the Duke Prostate Center Database

J. Moul, S. Freedland, Leon L Sun, 2010, BJU international.

Predicting non-organ-confined prostate cancer in men diagnosed after 2000

J. Moul, T. Polascik, C. Robertson, 2010, Prostate Cancer and Prostatic Diseases.

Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors.

A. D'Amico, Ming-Hui Chen, W. Catalona, 2009, International journal of radiation oncology, biology, physics.

Chapter 1 – Population Screening for Prostate Cancer and Early Detection in High-risk African American Men*

J. Moul, 2003 .

The role of radical prostatectomy in patients with pretreatment prostate-specific antigen > or = 40 ng/mL.

J. Moul, D. Mcleod, Hongyu Wu, 2002, Urologic oncology.

Introduction to Department of Defense Center for Prostate Disease Research Multicenter National Prostate Cancer Database, and analysis of changes in the PSA-era

J. Bishoff, J. Moul, C. Kane, 2001 .

Improvements in pathologic staging for African‐American men undergoing radical retropubic prostatectomy during the prostate specific antigen era

Laurence R. Paquette, J. Moul, R. Connelly, 2001, Cancer.

A comparison of radical retropubic with perineal prostatectomy for localized prostate cancer within the Uniformed Services Urology Research Group

J. Moul, C. Kane, J. Thrasher, 2001, BJU international.

Preoperative Predictors of Pathologic Stage T2a in Low-Risk Prostate Cancer: Implications for Focal Therapy

J. Moul, V. Mouraviev, T. Polascik, 2012, Urologia Internationalis.

Risk of death from prostate cancer after radical prostatectomy or brachytherapy in men with low- or intermediate-risk disease.

A. D'Amico, J. Moul, N. Arvold, 2011, Journal of Clinical Oncology.

Tumor percent involvement predicts prostate specific antigen recurrence after radical prostatectomy only in men with smaller prostate.

J. Moul, D. Albala, T. Polascik, 2010, The Journal of urology.

Role of salvage lymph node dissection in prostate cancer

J. Moul, R. Karnes, S. Shariat, 2016, Current opinion in urology.

Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer.

M. Morris, J. Moul, E. Small, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer.

M. Gleave, J. Nelson, J. Moul, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Contemporary Role of Multiparametric Magnetic Resonance Imaging in Active Surveillance for Prostate Cancer

Rajan T. Gupta, J. Moul, T. Polascik, 2017, Current Urology Reports.

Significance of tertiary Gleason pattern 5 in Gleason score 7 radical prostatectomy specimens.

J. Moul, W. Sexton, D. Whittemore, 2008, The Journal of urology.

Significant discrepancies between diagnostic and pathologic Gleason sums in prostate cancer: the predictive role of age and prostate-specific antigen.

J. Moul, D. Albala, J. Madden, 2008, Urology.

Watchful waiting and factors predictive of secondary treatment of localized prostate cancer.

Timothy F. Donahue, J. Moul, C. Amling, 2004, The Journal of urology.

Primary hormonal therapy for prostate cancer: experience with 135 consecutive PSA-ERA patients from a tertiary care military medical center

J. Moul, J. Bauer, R. Connelly, 2002, Prostate Cancer and Prostatic Diseases.

Adenocarcinoma of the prostate: an expensive way to die

J. Moul, J. Foley, T. Seay, 2002, Prostate Cancer and Prostatic Diseases.

Complete embedding and close step-sectioning of radical prostatectomy specimens both increase detection of extra-prostatic extension, and correlate with increased disease-free survival by stage of prostate cancer patients

J. Bishoff, F. Mostofi, J. Moul, 2002, Prostate Cancer and Prostatic Diseases.

Targeted Prostate Biopsy Using Statistical Image Analysis

Dinggang Shen, Gabor Fichtinger, Christos Davatzikos, 2007, IEEE Transactions on Medical Imaging.

Allelic loss on chromosome 6Q in primary prostate cancer

F. Mostofi, V. Srikantan, J. Moul, 1999, International journal of cancer.

Efficacy of radiographic chest imaging in patients with testicular cancer.

J. Moul, D. Mcleod, E. Colón, 1994, Urology.

Relationship between obesity and race in predicting adverse pathologic variables in patients undergoing radical prostatectomy.

J. Moul, J. Roberts, C. Amling, 2001, Urology.

Comparative studies of prostate cancers among United States, Chinese, and Japanese patients: characterization of histopathology, tumor angiogenesis, neuroendocrine factors, and p53 protein accumulations.

W. Fraser Symmans, J. Moul, P. Troncoso, 1995, Urologic oncology.

Prostate specific antigen kinetics at tumor recurrence after radical prostatectomy do not suggest a worse disease prognosis in black men.

J. Moul, D. Theodorescu, E. Bissonette, 2001, The Journal of urology.

Words of wisdom. Re: obesity-related plasma hemodilution and PSA concentration among men with prostate cancer.

J. Moul, 2008, European urology.

Obesity and oncological outcome after radical prostatectomy: impact of prostate‐specific antigen‐based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center Databases

M. Terris, J. Moul, S. Freedland, 2008, BJU international.

Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy.

Timothy F. Donahue, J. Moul, C. Amling, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic significance of DNA ploidy in carcinoma of prostate.

R. E. Cunningham, J. Moul, J. Lynch, 1989, Urology.

Factors predicting early and late phase decline of sexual health-related quality of life following radical prostatectomy.

J. Moul, T. Polascik, F. Schroeck, 2011, The journal of sexual medicine.

Initial prostate specific antigen 1.5 ng/ml or greater in men 50 years old or younger predicts higher prostate cancer risk.

J. Moul, D. Albala, T. Polascik, 2010, The Journal of urology.

Sexual bother and function after radical prostatectomy: predictors of sexual bother recovery in men despite persistent post‐operative sexual dysfunction

J. Moul, L. Gerber, L. Bañez, 2013, Andrology.

Editorial comment.

J. Moul, J. Semans, 2015, Urology.

Phase 3, randomized, placebo‐controlled study of zibotentan (ZD4054) in patients with castration‐resistant prostate cancer metastatic to bone

M. Gleave, J. Nelson, J. Moul, 2012, Cancer.

Percent tumor involvement and risk of biochemical progression after radical prostatectomy.

J. Moul, S. Freedland, J. Madden, 2008, The Journal of urology.

Timing and patterns of recurrences and deaths from prostate cancer following adjuvant pelvic radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate

P. Febbo, J. Moul, D. Albala, 2006, Prostate Cancer and Prostatic Diseases.

Effect of age and pathologic Gleason score on PSA recurrence: analysis of 2911 patients undergoing radical prostatectomy.

J. Moul, D. Albala, T. Polascik, 2009, Urology.

Delayed prostate-specific antigen recurrence after radical prostatectomy: how to identify and what are their clinical outcomes?

J. Moul, D. Albala, V. Mouraviev, 2009, Urology.

Can prostate-specific antigen and prostate-specific antigen velocity be used for prostate cancer screening in men older than 70 years?

J. Moul, V. Mouraviev, T. Polascik, 2008, Urology.

Outcomes research section Outcome research: prostate cancer databases

J. Moul, 2002 .

Advances in Brief PSGR , a Novel Prostate-specific Gene with Homology to a G Protein-coupled Receptor , Is Overexpressed in Prostate Cancer 1

Wei Zhang, M. Augustus, V. Srikantan, 2000 .

Cancer Protein-coupled Receptor , Is Overexpressed in Prostate , a Novel Prostate-specific Gene with Homology to a G PSGR Updated

M. Augustus, V. Srikantan, J. Moul, 2000 .

Tumor volume, tumor percentage involvement or prostate volume: Which is predictive of PSA recurrence?

J. Moul, D. Albala, V. Mouraviev, 2009 .

Race/Ethnicity and the Intensity of Medical Monitoring Under ‘Watchful Waiting’ for Prostate Cancer

V. Shavers, J. Moul, C. Klabunde, 2004, Medical care.

Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men.

F. Mostofi, J. Moul, S. Srivastava, 1995, JAMA.

Use of prostate-specific antigen in the follow-up of patients with localized prostate cancer: results of a nationwide survey of urologists.

J. Moul, D. Penson, D. Newling, 2006, Urology.

Counterpoint: Which Treatment Modality for Localized Prostate Cancer Yields Superior Quality of Life: Radiotherapy or Prostatectomy? Most Men With Clinically Important Localized Prostate Cancer Deserve First-Line Open or Robotic Radical Prostatectomy.

J. Moul, 2017, Oncology.

Radical perineal prostatectomy for the treatment of localized prostate cancer in morbidly obese patients.

J. Moul, P. Dahm, T. Gan, 2005, The Journal of urology.

Targeting the androgen receptor--theory and practice.

A. Kibel, J. Moul, J. Thrasher, 2011, Urology.

Supplement Article Indications and Practice With Androgen Deprivation Therapy

A. Kibel, J. Moul, M. Roach, 2011 .

Indications and practice with androgen deprivation therapy.

A. Kibel, J. Moul, M. Roach, 2011, Urology.

Supplement Article Targeting the Androgen Receptor—Theory and Practice

A. Kibel, J. Moul, J. Thrasher, 2011 .

Association between percentage of tumor involvement and Gleason score upgrading in low-risk prostate cancer

J. Moul, V. Mouraviev, T. Polascik, 2012, Medical Oncology.

Active surveillance for prostate cancer: can we modernize contemporary protocols to improve patient selection and outcomes in the focal therapy era?

J. Moul, T. Polascik, K. Tay, 2015, Current opinion in urology.

The Impact of Late Luteinizing Hormone-Releasing Hormone Agonist Dosing on Testosterone Suppression in Patients with Prostate Cancer: An Analysis of United States Clinical Data

E. Crawford, J. Moul, C. Higano, 2020 .

Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer.

M. Gleave, J. Nelson, J. Moul, 2012, The Journal of urology.

Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics.

E. Crawford, J. Moul, F. Schröder, 2010, European urology.

High-risk prostate cancer and radical prostatectomy in the setting and context of multidisciplinary care.

J. Moul, 2015, Urologic oncology.

Use of prostate-specific antigen in black men: age-adjusted reference ranges for maximal cancer detection.

J. Moul, 1998, Journal of the National Medical Association.

Preoperative predictors of pathologic stage T2a and pathologic Gleason score ≤ 6 in men with clinical low-risk prostate cancer treated with radical prostatectomy: reference for active surveillance

J. Moul, V. Mouraviev, T. Polascik, 2013, Medical Oncology.

Emerging treatment options for patients with castration‐resistant prostate cancer

J. Moul, D. George, 2012, The Prostate.

New data, new paradigms for treating prostate cancer patients--VI: novel hormonal therapy approaches.

J. Moul, D. Bajorin, D. Petrylak, 2011, Urology.

Neural network analysis of quantitative histological factors to predict pathological stage in clinical stage I nonseminomatous testicular cancer.

J W Moul, J. Moul, I. Sesterhenn, 1995, The Journal of urology.

Percentage of embryonal carcinoma and of vascular invasion predicts pathological stage in clinical stage I nonseminomatous testicular cancer.

J. Moul, I. Sesterhenn, I. Sesterhenn, 1994, Cancer research.

Diagnostic potential of prostate-specific antigen expressing epithelial cells in blood of prostate cancer patients.

J. Moul, S. Srivastava, R. Connelly, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

No-Shows in Adult Urology Outpatient Clinics: Economic and Operational Implications.

Tracy X. Han, J. Moul, G. Faerber, 2020, Urology practice.

Prostate cancer in the late 1990s: hormone refractory disease options.

J. Moul, D. R. Lipo, 1999, Urologic nursing.

Bone Complications in Prostate Cancer: Current and Future Role of Bisphosphonates

J. Moul, F. Saad, 2005, Current Oncology.

Flaxseed-derived enterolactone is inversely associated with tumor cell proliferation in men with localized prostate cancer.

M. Dewhirst, J. Moul, W. Demark-Wahnefried, 2013, Journal of medicinal food.

Diagnostic potential of serum proteomic patterns in prostate cancer.

Bao-Ling Adam, Amina Ali, J. Moul, 2003, The Journal of urology.

Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome

V. Srikantan, J. Moul, S. Srivastava, 2006, Oncogene.

Phase III study of the efficacy and safety of zibotentan (ZD4054) in patients with bone metastatic castration-resistant prostate cancer (CRPC).

M. Gleave, J. Nelson, J. Moul, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

How I do it: Apalutamide use in non-metastatic castrate resistant prostate cancer.

J. Moul, 2019, The Canadian journal of urology.

Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens

P. Schellhammer, J. Moul, C. Higano, 2018, The Journal of urology.

Effects of nonlinear aerobic training on erectile dysfunction and cardiovascular function following radical prostatectomy for clinically localized prostate cancer.

Jason D. Allen, J. Moul, S. Freedland, 2014, European urology.

Use of glycosylated hemoglobin to identify diabetics at high risk for penile periprosthetic infections.

J. Moul, D. Mcleod, D. Peppas, 1992, The Journal of urology.

Increased p53 protein does not correlate to p53 gene mutations in microdissected human testicular germ cell tumors.

J. Moul, S. Srivastava, I. Sesterhenn, 1995, The Journal of urology.

Immunohistochemical and mutational analysis of the p53 tumour suppressor gene and the bcl‐2 oncogene in primary testicular germ cell tumours

J. Moul, S. Srivastava, U. Engelmann, 1998, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

Expression profile of an androgen regulated prostate specific homeobox gene NKX3.1 in primary prostate cancer.

M. Augustus, V. Srikantan, J. Moul, 2000, The Journal of urology.

Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12‐month, comparative, phase III study

E. Crawford, J. Moul, F. Schröder, 2009, BJU international.

Testicular cancer in blacks. A multicenter experience

J. Moul, K. Kreder, R. Stack, 1994 .

A long-term study of the efficacy of treatment of localized prostate cancer.

I. Thompson, J. Moul, K. Kreder, 1997, Urologic oncology.

Prostate-Specific Antigen as a Marker of Disease Activity in Prostate Cancer : Part 1 Review

A. Partin, H. Scher, J. Moul, 2017 .

Timely diagnosis of testicular cancer.

J. Moul, 2007, The Urologic clinics of North America.

Molecular implications of the antiandrogen withdrawal syndrome.

J. Moul, D. Mcleod, S. Srivastava, 1995, Seminars in urology.

Radical prostatectomy for clinical stage T1-2N0M0 prostatic adenocarcinoma: long-term results.

J. Moul, D. Paulson, P. Walther, 1990, The Journal of urology.

Tortuous and aberrant external iliac artery precluding radical retropubic prostatectomy for prostate cancer.

J. Moul, G. Wind, C. Wright, 1993, Urology.

Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure.

A. D'Amico, P. Carroll, Ming-Hui Chen, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Open radical retropubic prostatectomy 2007: the true minimally invasive surgery for localized prostate cancer?

J. Moul, T. Gan, I. Nosnik, 2007, Expert review of anticancer therapy.

Does the multidisciplinary approach improve oncological outcomes in men undergoing surgical treatment for prostate cancer?

J. Moul, S. Freedland, A. Armstrong, 2014, International journal of urology : official journal of the Japanese Urological Association.

Recombinant adenovirus vector expressing wild-type p53 is a potent inhibitor of prostate cancer cell proliferation.

J. Moul, S. Srivastava, Y. Tong, 1995, Urology.

Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer.

J. Moul, S. Srivastava, I. Sesterhenn, 1995, The Journal of urology.

What to order from the prostate cancer treatment menu?

J. Moul, A. Armstrong, D. George, 2012, Oncology.

Optimizing the efficiency and quality of sipuleucel-T delivery in an academic institution.

M. Harrison, J. Moul, A. Armstrong, 2015, Clinical journal of oncology nursing.

A phase 3, placebo controlled study of the safety and efficacy of avanafil for the treatment of erectile dysfunction after nerve sparing radical prostatectomy.

J. Moul, K. McVary, J. Mulhall, 2013, The Journal of urology.

Diagnosis, staging, and risk factors: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009.

P. Albers, J. Moul, F. Algaba, 2011, Urology.

Complications of therapy for testicular cancer.

J. Moul, S. George, D. Paulson, 1989, The Journal of urology.

Prognostic value of BHCG and local tumor invasion in stage I seminoma of the testis

J. Moul, J. Thrasher, B. Schwartz, 1996, Journal of surgical oncology.

The role of retroperitoneal lymphadenectomy in mature teratoma of the testis.

F. Mostofi, J. Moul, U. Engelmann, 1997, The Journal of urology.

Retroperitoneal imaging with third and fourth generation computed axial tomography in clinical stage I nonseminomatous germ cell tumors.

J. Moul, D. Mcleod, J. Foley, 1994, Urology.

Contralateral testicular biopsy procedure in patients with unilateral testis cancer: is it indicated?

J. Moul, A. Heidenreich, 2002, Seminars in urologic oncology.

A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer.

E. Crawford, J. Moul, F. Schröder, 2011, The Journal of urology.

Prognostic factors in low-stage nonseminomatous testicular cancer.

J. Moul, A. Heidenreich, 1996, Oncology.

Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis

F. Mostofi, J. Moul, I. Sesterhenn, 1998, Cancer.

Biomarkers Accurately Inform Treatment Decisions in Localized Prostate Cancer.

J. Moul, 2022, European urology focus.

Molecular Mechanisms of Castrate-Resistant Prostate Cancer.

J. Moul, A. Armstrong, T. Polascik, 2022, The Urologic clinics of North America.

Initial Longitudinal Outcomes of Risk-Stratified Men in Their Forties Screened for Prostate Cancer Following Implementation of a Baseline Prostate-Specific Antigen

Rajan T. Gupta, J. Moul, G. Preminger, 2022, The world journal of men's health.

The influence of ejaculation on serum levels of prostate specific antigen.

J. Moul, U. Engelmann, A. Heidenreich, 1997, The Journal of urology.

Hormone naïve prostate cancer: predicting and maximizing response intervals

J. Moul, 2015, Asian journal of andrology.

Initiation of salvage therapy for prostate cancer

J. Moul, C. Amling, C. Kane, 2002, Prostate Cancer and Prostatic Diseases.

Significance of familial history of prostate cancer to traditional prognostic variables, genetic biomarkers, and recurrence after radical prostatectomy.

J. Moul, S. Srivastava, J. Bauer, 1998, Urology.

Benign prostatic hyperplasia.

J. Moul, 1993, Postgraduate medicine.

Prostate Biopsy Protocols: 3D Visualization-Based Evaluation and Clinical Correlation

Wei Zhang, J. Moul, S. Mun, 2001 .

Relationship between body mass index and prostate cancer screening in the United States.

K. Schulman, J. Moul, P. Dahm, 2007, The Journal of urology.

Urinary microbiota and prostatic diseases: the key for the lock? A systematic review

J. Moul, K. McVary, S. Albisinni, 2022, Prostate Cancer and Prostatic Diseases.

1724 INITIAL PSA >= 1.5 NG/ML IN MEN =< 50 YEARS OLD PREDICTS A SUBSEQUENT HIGHER RISK OF PROSTATE CANCER

J. Moul, D. Albala, T. Polascik, 2010 .

Defining potency: A comparison of the International Index of Erectile Function short version and the Expanded Prostate Cancer Index Composite

J. Moul, D. Albala, T. Polascik, 2008, Cancer.

Retroaortic left renal vein in testicular cancer patient: potential staging and treatment pitfall.

J. Moul, D. Hartman, M. Maggio, 1992, The Journal of urology.

ADT risks and side effects in advanced prostate cancer: cardiovascular and acute renal injury.

E. Crawford, J. Moul, 2015, Oncology.

Phase 2 Study of Weekly Paclitaxel Plus Estramustine in Metastatic Hormone‐Refractory Prostate Carcinoma: ECOG‐ACRIN Cancer Research Group (E1898) Trial

J. Manola, D. Cella, J. Moul, 2017, Clinical genitourinary cancer.

PSA thresholds for prostate cancer detection.

J. Moul, 1997, JAMA.

Transitional cell carcinomatous meningitis after M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) chemotherapy.

J. Moul, D. Mcleod, J. Bishop, 1990, Urology.

Suramin keratosis: a unique skin eruption in a patient receiving suramin for metastatic prostate cancer.

J. Moul, N. Dawson, L. Sperling, 1997, The Journal of urology.

Combined low‐dose flutamide plus finasteride vs low‐dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long‐term follow‐up

E. Crawford, J. Moul, D. Mcleod, 2009, BJU international.

New data, new paradigms for treating patients with prostate cancer. Conclusion.

J. Moul, R. Dreicer, 2011, Urology.

Castration-resistant prostate cancer: Why should urologists care?

J. Moul, 2016 .

Prostate cancer: Making the switch from LHRH antagonist to LHRH agonist

J. Moul, 2012, Nature Reviews Urology.

Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy.

A. Zietman, J. Moul, A. Briganti, 2012, European urology.

Artificial Neural Networks in Urologic Oncology

Judd W. Moul, Thomas H. Douglas, J. Moul, 2001 .

Experience with the AMS 600 malleable penile prosthesis.

J. Moul, D. Mcleod, 1986, The Journal of urology.

Use of Glycosylated Hemoglobin to Identify Diabetics at High Risk for Penile Periprosthetic Infections

J. Moul, D. Mcleod, D. Peppas, 1992 .

Transdermal Nicotine for Analgesia After Radical Retropubic Prostatectomy

W. White, J. Moul, T. Polascik, 2008, Anesthesia and analgesia.

Proliferating cell nuclear antigen expression to predict occult disease in clinical stage I nonseminomatous testicular germ cell tumors.

F. Mostofi, J. Moul, I. Sesterhenn, 1994, The Journal of urology.

MOLECULAR ANALYSIS OF P16Ink4/CDKN2 AND P15Ink4B/MTS2 GENES IN PRIMARY HUMAN TESTICULAR GERM CELL TUMORS

J. Moul, S. Srivastava, A. Heidenreich, 1998 .

Prostate Cancer Satisfaction and Regret after Open Retropubic or Robot-Assisted Laparoscopic Radical Prostatectomy

J. Moul, D. Albala, T. Polascik, 2008 .

Synchronous bilateral testicular tumour: nonseminomatous germ cell tumours and contralateral benign tumours.

J. Moul, S. Srivastava, U. Engelmann, 1997, Scandinavian journal of urology and nephrology.

Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy.

J. Moul, C. Amling, W. Sexton, 2008, The Journal of urology.

The role of radical surgery in the management of radiation recurrent and large volume prostate cancer

J. Moul, D. Paulson, 1991, Cancer.

Aneuploidy of Chromosome 9 and the Tumor Suppressor Genes p16INK4 and p15INK4B Detected by in situ Hybridization in Locally Advanced Prostate Cancer

J. Moul, S. Srivastava, I. Sesterhenn, 2000, European Urology.

Mutations of the p16 gene product are rare in prostate cancer

J. Moul, S. Srivastava, I. Sesterhenn, 1997, The Prostate.

Disparate results between proliferation rates of surgically excised prostate tumors and an in vitro bioassay using sera from a positive randomized controlled trial

J. Moul, J. Moul, W. Demark-Wahnefried, 2015, Biotechnic & histochemistry : official publication of the Biological Stain Commission.

Celiac axis and superior mesenteric artery injury associated with left radical nephrectomy for locally advanced renal cell carcinoma.

J. Moul, D. Mcleod, J. Foley, 1991, The Journal of urology.

Screening for familial and hereditary prostate cancer

A. D'Amico, S. Leslie, W. Isaacs, 2016, International journal of cancer.

Candida albicans corpora abscess following penile prosthesis placement.

J. Moul, D. Mcleod, D. Peppas, 1988, Journal of Urology.

Immunomodulatory lipid mediator profiling of cerebrospinal fluid following surgery in older adults

Jeffrey N. Browndyke, Michael N. Ferrandino, J. Moul, 2021, Scientific reports.

Curcumin down-regulates AR gene expression and activation in prostate cancer cell lines.

J. Rhim, J. Moul, S. Srivastava, 2002, International journal of oncology.

Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology

M. Kattan, F. Saad, J. Moul, 2010, BJU international.

Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer.

F. Mostofi, J. Moul, S. Srivastava, 1996, Surgery.

New tumor markers of testis cancer.

J. Moul, R. Dean, 1998, The Urologic clinics of North America.

Immunohistochemical expression of monoclonal antibody 43-9F in testicular germ cell tumours.

F. Mostofi, J. Moul, I. Sesterhenn, 2002, International journal of andrology.

Immunohistochemical expression of Ki-67 to predict lymph node involvement in clinical stage I nonseminomatous germ cell tumors.

F. Mostofi, J. Moul, I. Sesterhenn, 1997, The Journal of urology.

Molecular Genetic Parameters in Pathogenesis and Prognosis of Testicular Germ Cell Tumors

J. Moul, S. Srivastava, A. Heidenreich, 2000, European Urology.

Prognostic risk factors in low stage testicular germ cell tumors

J. Moul, I. Sesterhenn, A. Heidenreich, 1997, Cancer.

Immunohistochemical expression of P53 tumor suppressor gene protein in adult germ cell testis tumors: clinical correlation in stage I disease.

J W Moul, J. Moul, I. Sesterhenn, 1994, The Journal of urology.

Flow cytometric and quantitative histological parameters to predict occult disease in clinical stage I nonseminomatous testicular germ cell tumors.

J. Moul, I. Sesterhenn, W. Mccarthy, 1993, The Journal of urology.

A review of surgical treatment of undescended testes with emphasis on anatomical position.

J. Moul, A. Belman, 1988, The Journal of urology.

The impact of the “cisplatin era” of treatment on survival in testicular cancer

J. Moul, R. Dodge, D. Paulson, 1991, World Journal of Urology.

CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy.

J. Moul, J. Bauer, R. Connelly, 1998, The Journal of urology.

Immunohistologic detection of prostate cancer pelvic lymph node micrometastases: correlation to preoperative serum prostate-specific antigen.

J. Moul, D. J. Lewis, D. Mcleod, 1994, Urology.

[Histopathologic and biological prognostic factors of clinical stage I non-seminomatous germ cell tumors. Implications for risk-adjusted therapy].

F. Mostofi, J. Moul, I. Sesterhenn, 1999, Der Urologe. Ausg. A.

Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy.

Ming-Hui Chen, Anthony V D'Amico, A. D'Amico, 2003, Journal of the National Cancer Institute.

Testicular tumour.

J. Moul, 1992, British journal of hospital medicine.

Prostate cancer with solitary parotid metastasis correctly diagnosed with immunohistochemical stains.

J. Moul, M. Gottfried, D. Paulson, 1989, The Journal of urology.

Clinically detected carcinoma of the prostate treated by radical prostatectomy in a 29-year-old man.

F. Mostofi, J. Moul, D. Mcleod, 1994, The Journal of urology.

Population screening for prostate cancer and emerging concepts for young men.

J. Moul, Judd W Moul, 2003, Clinical prostate cancer.

Infrequent RAS oncogene mutations in human prostate cancer

J W Moul, J. Moul, E. Chang, 1992, The Prostate.

Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome

V. Srikantan, J. Moul, S. Srivastava, 2005, Oncogene.

Molecular Genetics and Markers of Progression

M. Augustus, J. Moul, S. Srivastava, 2000 .

Chapter 8 Molecular progression of prostate cancer

J. Moul, S. Srivastava, 1999 .

Effects of family history and genetic polymorphism on the cost-effectiveness of chemoprevention with finasteride for prostate cancer.

K. Schulman, Jianfeng Xu, Jielin Sun, 2011, The Journal of urology.

Postoperative prostate‐specific antigen nadir improves accuracy for predicting biochemical recurrence after radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) and Duke Prostate Center databases

M. Terris, J. Moul, S. Freedland, 2010, International journal of urology : official journal of the Japanese Urological Association.

Tumor volume, tumor percentage involvement, or prostate volume: which is predictive of prostate-specific antigen recurrence?

Robin Vollmer, J. Moul, D. Albala, 2010, Urology.

Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy.

M. Terris, B. Trock, A. Partin, 2009, The Journal of urology.

Factors predicting prostatic biopsy Gleason sum under grading.

Cyril O. Acholo, J. Moul, D. Albala, 2009, The Journal of urology.

Update on outcomes research databases in prostate cancer 2006

J. Moul, S. Freedland, T. Krupski, 2006, Current opinion in urology.

Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy.

A. D'Amico, D. Lubeck, P. Carroll, 2004, The Journal of urology.

The evolving definition of advanced prostate cancer.

J. Moul, 2004, Reviews in urology.

Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era.

A. D'Amico, D. Lubeck, P. Carroll, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PSA progression following radical prostatectomy and radiation therapy: new standards in the new Millennium.

Mesut Remzi, Bob Djavan, J. Moul, 2003, European urology.

Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases.

D. Lubeck, P. Carroll, J. Moul, 2001, The Journal of urology.

Prostate specific antigen only progression of prostate cancer.

J. Moul, 2000, The Journal of urology.

Angiogenesis, p53, bcl-2 and Ki-67 in the Progression of Prostate Cancer after Radical Prostatectomy

J. Moul, 1999, European Urology.

Molecular Targets for Chemoprevention of Prostate Cancer

J. Moul, 1999 .

Prostate Cancer SEER Incidence of Distant Disease

J. Moul, 1997 .

Biostatistical modeling using traditional variables and genetic biomarkers for predicting the risk of prostate carcinoma recurrence after radical prostatectomy

J. Moul, S. Srivastava, J. Bauer, 1997, Cancer.

Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting.

J. Moul, W. Mccarthy, D. Mcleod, 1996, The Journal of urology.

Characterization of frequently deleted 6q locus in prostate cancer.

J. Strovel, M. Augustus, Wei Zhang, 2006, DNA and cell biology.

A Randomized Controlled Trial of a 6-Month Low-Carbohydrate Intervention on Disease Progression in Men with Recurrent Prostate Cancer: Carbohydrate and Prostate Study 2 (CAPS2)

P. Lin, J. Moul, H. Sandler, 2020, Clinical Cancer Research.

Focal p53 protein expression and lymphovascular invasion in primary prostate tumors predict metastatic progression

Cara C. Schafer, J. Moul, S. Srivastava, 2022, Scientific Reports.

Utilizing Biopsy-Based Genomic Assays to Risk-Stratify Patients

J. Moul, S. Freedland, Robert Qi, 2017 .

High-Risk Prostate Cancer: Role of Radical Prostatectomy and Radiation Therapy

J. Moul, Robert Qi, 2015, Oncology Research and Treatment.

Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes.

Anthony V D'Amico, Javier Hernandez, Arthur L Burnett, 2007, The Journal of urology.

Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting function, is associated with high-risk prostate cancer patients

Wei Zhang, V. Srikantan, J. Moul, 2004, Oncogene.

Postoperative changes in cognition and cerebrospinal fluid neurodegenerative disease biomarkers

Jeffrey N. Browndyke, L. Shaw, J. Moul, 2022, Annals of clinical and translational neurology.

Androgen-induced expression of endoplasmic reticulum (ER) stress response genes in prostate cancer cells

Wei Zhang, Wei Zhang, J. Moul, 2002, Oncogene.

TITLE: Cerebrospinal Fluid Proteome Changes in Older Non-Cardiac Surgical Patients with Postoperative Cognitive Dysfunction RUNNING TITLE: Cerebrospinal Fluid Proteome Changes after Surgery AUTHORS:

Jeffrey N. Browndyke, Michael N. Ferrandino, Yi-Ju Li, 2021 .

Determining optimal prostate-specific antigen thresholds to identify an increased 4-year risk of prostate cancer development: an analysis within the Veterans Affairs Health Care System

J. Hardin, J. Moul, E. Crawford, 2016, World Journal of Urology.

Relationship Between Depression/Anxiety and Cognitive Function Before and 6 Weeks After Major Non-Cardiac Surgery in Older Adults

Jeffrey N. Browndyke, H. Cohen, J. Moul, 2020, Journal of geriatric psychiatry and neurology.

PSGR, a novel prostate-specific gene with homology to a G protein-coupled receptor, is overexpressed in prostate cancer.

W. Zhang, M. Augustus, V. Srikantan, 2000, Cancer research.

Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma.

J. Moul, I. Sesterhenn, E. Chang, 1993, The Journal of urology.

A novel neoplastic primary tumor-derived human prostate epithelial cell line.

J. Rhim, J. Moul, S. Srivastava, 2003, International journal of oncology.

Treatment of PSA only recurrence of prostate cancer after prior local therapy.

J. Moul, 2006, Current pharmaceutical design.

Obese men have higher-grade and larger tumors: an analysis of the duke prostate center database

J. Moul, S. Freedland, L. Bañez, 2009, Prostate Cancer and Prostatic Diseases.

A protocol to reduce self-reported pain scores and adverse events following lumbar punctures in older adults

Jeffrey N. Browndyke, H. Cohen, M. Berry, 2020, Journal of Neurology.

Prostatic Alpha-Linolenic Acid (ALA) Is Positively Associated with Aggressive Prostate Cancer: A Relationship Which May Depend on Genetic Variation in ALA Metabolism

J. Moul, W. Demark-Wahnefried, J. Madden, 2012, PloS one.

Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer.

F. Mostofi, J. Moul, S. Srivastava, 1996, The Journal of urology.

Quantitative expression profile of androgen‐regulated genes in prostate cancer cells and identification of prostate‐specific genes

J. Moul, S. Srivastava, D. Mcleod, 2001, International journal of cancer.

Overview Prostate cancer is the most commonly diagnosed The NCCN Prostate Cancer Early Detection Clinical Practice Guidelines in OncologyTM

John T. Wei, P. Carroll, Ruth Etzioni, 2010 .

Prostate cancer early detection

Antoinette M Stroup, William J Catalona, James Mohler, 2010 .

A Human Novel Gene DERPC Located on 16q22.1 Inhibits Prostate Tumor Cell Growth and Its Expression Is Decreased in Prostate and Renal Tumors

Wei Zhang, Wei Zhang, J. Moul, 2002, Molecular medicine.

Prostate-Specific Antigen as a Marker of Disease Activity in Prostate Cancer : Part 2

A. Partin, H. Scher, J. Moul, 2017 .

Prostate-Specific Antigen as a Marker of Disease Activity in Prostate Cancer : Part 2 Review

A. Partin, H. Scher, J. Moul, 2017 .

Prostate-specific antigen as a marker of disease activity in prostate cancer.

Alan W Partin, A. Partin, H. Scher, 2002, Oncology.

Prostate‐specific antigen screening among young men in the United States

K. Schulman, J. Moul, L. Curtis, 2008, Cancer.

Effect of age on biochemical disease-free outcome in patients with T1-T3 prostate cancer treated with definitive radiotherapy in an equal-access health care system: a radiation oncology report of the Department of Defense Center for Prostate Disease Research.

J. Moul, C. Amling, C. Kane, 2003, International journal of radiation oncology, biology, physics.

Prostate cancer in men age 50 years or younger: a review of the Department of Defense Center for Prostate Disease Research multicenter prostate cancer database.

J. Moul, J. Bauer, R. Connelly, 2000, The Journal of urology.

A guide for clinicians in the evaluation of emerging molecular diagnostics for newly diagnosed prostate cancer.

P. Febbo, A. Kibel, J. Moul, 2014, Reviews in urology.

Histopathological and biological prognostic risk factors in low stage testicular nonseminomatous germ cell tumors

F. Mostofi, J. Moul, I. Sesterhenn, 1999, Der Urologe.

Inflammatory infiltrate (prostatitis) in whole mounted radical prostatectomy specimens from black and white patients is not an etiology for racial difference in prostate specific antigen.

F. Mostofi, J. Moul, R. Connelly, 2000, The Journal of urology.

Molecular analysis of P16(Ink4)/CDKN2 and P15(INK4B)/MTS2 genes in primary human testicular germ cell tumors.

J. Moul, S. Srivastava, A. Heidenreich, 1998, The Journal of urology.

The changing face of prostate cancer.

M. Cooperberg, P. Carroll, J. Moul, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A novel human cancer culture model for the study of prostate cancer

J. Rhim, J. Moul, S. Srivastava, 2001, Oncogene.

Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.

P. Kantoff, M. Cooperberg, T. Rebbeck, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NADiA ProsVue prostate-specific antigen slope, CAPRA-S, and prostate cancer--specific survival after radical prostatectomy.

J. Moul, M. A. Reynolds, M. Sarno, 2014, Urology.

Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group.

A. D'Amico, P. Kantoff, K. Pienta, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature.

A. D'Amico, M. Cooperberg, H. Scher, 2013, European urology.

A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes.

B. Guillonneau, J. Eastham, S. Boorjian, 2012, European urology.

Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy.

J. Moul, C. Amling, C. Kane, 2003, Urology.

Polymer‐delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open‐label studies in patients with advanced prostate cancer

E. Crawford, J. Moul, N. Shore, 2017, BJU international.

Impact of Late Dosing on Testosterone Suppression with Two Different Leuprolide Acetate Formulations: In Situ Gel and Microsphere - An Analysis of US Clinical Data.

E. Crawford, J. Moul, C. Higano, 2020, The Journal of urology.

Subcutaneous in situ gel delivered leuprolide acetate's consistent and prolonged drug delivery maintains effective testosterone suppression independent of age and weight in men with prostate cancer

J. Moul, S. Tagawa, D. Boldt‐Houle, 2020, BJUI compass.

Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl

E. Crawford, J. Moul, O. Sartor, 2015, Expert opinion on drug metabolism & toxicology.

Utility of LHRH antagonists for advanced prostate cancer.

J. Moul, 2014, The Canadian journal of urology.

Radical prostatectomy vs radiation therapy and androgen‐suppression therapy in high‐risk prostate cancer

A. D'Amico, Ming-Hui Chen, K. Westover, 2012, BJU international.

Review: Risk stratification in the hormonal treatment of patients with prostate cancer

J. Moul, Leon L Sun, P. Tang, 2009, Therapeutic advances in medical oncology.

Point: radical prostatectomy is the treatment of choice for high-risk prostate cancer patients.

J. Moul, 2008, Brachytherapy.

Awareness, concern, and communication between physicians and patients on bone health in cancer

J. Moul, D. Tripathy, B. Durie, 2014, Supportive Care in Cancer.

Lidocaine Patch for Postoperative Analgesia After Radical Retropubic Prostatectomy

W. White, J. Moul, T. Polascik, 2009, Anesthesia and analgesia.

Multicenter patient self-reporting questionnaire on impotence, incontinence and stricture after radical prostatectomy.

J W Moul, J. Moul, J. Thrasher, 2000, The Journal of urology.

The contemporary value of pretreatment prostatic acid phosphatase to predict pathological stage and recurrence in radical prostatectomy cases.

J. Moul, R. Connelly, D. Mcleod, 1998, The Journal of urology.

Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy.

A. D'Amico, P. Carroll, Ming-Hui Chen, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A retrospective comparison of anesthetic management of robot-assisted laparoscopic radical prostatectomy versus radical retropubic prostatectomy.

J. Moul, D. Albala, P. Dahm, 2009, Journal of clinical anesthesia.

Contemporary Radical Prostatectomy

Judd W. Moul, J. Moul, Qiang Fu, 2011, Prostate cancer.

Rising prostate-specific antigen after primary prostate cancer therapy

J. Moul, J. Ward, 2005, Nature Clinical Practice Urology.

Gossypiboma (retained surgical sponge) and recurrent bladder neck contracture after radical retropubic prostatectomy and bilateral pelvic lymph node dissection.

J. Moul, P. Irby, H. B. Heidenberg, 1997, The Journal of urology.

Adrenal cortical carcinoma with vena cava tumor thrombus requiring cardiopulmonary bypass for resection.

J. Moul, D. Mcleod, M. Hardy, 1991, Urology.

Flaxseed Supplementation (Not Dietary Fat Restriction) Reduces Prostate Cancer Proliferation Rates in Men Presurgery

K. Owzar, L. Minasian, J. Moul, 2008, Cancer Epidemiology Biomarkers & Prevention.

Androgen and androgen receptor antagonist responsive primary African-American benign prostate epithelial cell line.

J. Rhim, J. Moul, S. Srivastava, 2005, Anticancer research.

Prostate‐specific antigen‐detected prostate cancer (Stage T1c): An analysis of whole‐mount prostatectomy specimens

J. Moul, R. Connelly, I. Sesterhenn, 1997, The Prostate.

p53 Regulates the Expression of the Tumor Suppressor Gene Maspin*

E. Appella, J. Moul, A. K. Nagaich, 2000, The Journal of Biological Chemistry.

Inhibition of the growth of pre‐established subcutaneous tumor nodules of human prostate cancer cells by single injection of the recombinant adenovirus p53 expression vector

J. Moul, S. Srivastava, I. Sesterhenn, 1997, International journal of cancer.

p53‐dependent induction of heat shock protein 27 (HSP27) expression

J. Moul, S. Srivastava, P. Seth, 2000, International journal of cancer.

EVALUATION OF REVERSE TRANSCRIPTASE (RT)-POLYMERASE CHAIN REACTION (PCR)-PROSTATE SPECIFIC ANTIGEN (PSA) ASSAY IN EPITHELIAL CELLS ISOLATED FROM PERIPHERAL BLOOD OF PROSTATE CANCER (CaP) PATIENTS

J. Moul, S. Srivastava, D. Mcleod, 1999 .

Management of Prostate Cancer in the Elderly.

J. Moul, A. Armstrong, K. Tay, 2016, Clinics in geriatric medicine.

Testosterone in prostate cancer: the Bethesda consensus

J. Eastham, J. Moul, S. Taneja, 2012, BJU international.

Absence of a correlation of androgen receptor gene CAG repeat length and prostate cancer risk in an African-American population.

J. Manola, P. Kantoff, J. Moul, 2004, Clinical prostate cancer.

Population Screening for Prostate Cancer and Early Detection

J. Moul, 2016 .

Predictive value of digital rectal examination for prostate cancer detection is modified by obesity

J. Moul, S. Freedland, D. Moreira, 2011, Prostate Cancer and Prostatic Diseases.

Limitations of tissue microarrays in the evaluation of focal alterations of bcl-2 and p53 in whole mount derived prostate tissues.

J. Serth, F. Mostofi, C. Bokemeyer, 2003, Oncology reports.

A novel androgen-regulated gene, PMEPA1, located on chromosome 20q13 exhibits high level expression in prostate.

J W Moul, J. Moul, S. Srivastava, 2000, Genomics.

Pathologic stage T2a and T2b prostate cancer in the recent prostate‐specific antigen era: Implications for unilateral ablative therapy

J. Moul, J. Madden, V. Mouraviev, 2008, The Prostate.

Prostate cancer‐specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high‐risk factors

A. D'Amico, Ming-Hui Chen, W. Catalona, 2007, Cancer.

Diagnostic accuracy of prostate needle biopsy

Timothy F. Donahue, J. Moul, T. Donahue, 2002, Current urology reports.

Acute urinary retention associated with prostatic carcinoma.

J. Moul, D. Mcleod, R. Davis, 1989, The Journal of urology.

Direct Measurement of Peptide-Specific CD8+ T Cells Using HLA-A2:Ig Dimer for Monitoring the In Vivo Immune Response to a HER2/neu Vaccine in Breast and Prostate Cancer Patients

J. Moul, C. Shriver, G. Peoples, 2004, Journal of Clinical Immunology.

Re-thinking How We Use Prostate Health Index for African American Men.

J. Moul, T. Polascik, S. Kotamarti, 2022, Urology.

Does mpMRI improve clinical criteria in selecting men with prostate cancer for active surveillance?

J. Moul, T. Polascik, T. Polascik, 2017, Prostate Cancer and Prostatic Diseases.

NCCN Prostate Cancer Early Detection Panel Members

P. Carroll, J. Moul, R. Bahnson, 2001 .

Screening for prostate cancer in high risk populations.

W. Catalona, J. Moul, K. Roehl, 2002, The Journal of urology.

Screening for prostate cancer in military populations.

J. Moul, 2005, Military medicine.

A discussion of general prostate cancer screening versus targeted diagnosis in younger men

J. Moul, 2005 .

Defining an Optimum PSA-Based Screening Strategy for Young Men

J. Moul, 2004 .

Prostate-specific antigen levels in young white and black men 20 to 45 years old.

J. Moul, G. Murphy, D. Jacobson, 2000, Urology.

Patient selection for hemiablative focal therapy of prostate cancer

J. Moul, J. Madden, V. Mouraviev, 2009, Cancer.

Predicting participation in and successful outcome of a penile rehabilitation programme using a phosphodiesterase type 5 inhibitor with a vacuum erection device after radical prostatectomy

J. Moul, T. Polascik, Ž. Vujašković, 2012, BJU international.

Putting Provenge in perspective.

J. Moul, 2011, Oncology.

Race is associated with discontinuation of active surveillance of low-risk prostate cancer: Results from the Duke Prostate Center

Michael N. Ferrandino, J. Moul, S. Freedland, 2012, Prostate Cancer and Prostatic Diseases.

Synchronous bilateral testis tumor: mixed germ cell and theca cell tumors.

J. Moul, N. Schenkman, C. K. Ho, 1993, Urology.

Predictors of extracapsular extension and positive margins in African American and white men.

Laurence R. Paquette, J. Moul, R. Connelly, 2003, Urologic oncology.

Navigating MRI-TRUS fusion biopsy: optimizing the process and avoiding technical pitfalls

Kae Jack Tay, Rajan T. Gupta, J. Moul, 2016, Expert review of anticancer therapy.

Quantitative expression profile of PSGR in prostate cancer

J. Moul, I. Sesterhenn, W. Zhang, 2006, Prostate Cancer and Prostatic Diseases.

Hepatic dysfunction following busulfan and cyclophosphamide myeloablation: a retrospective, multicenter analysis.

J. Moul, J. Szer, E. Copelan, 1996, Bone marrow transplantation.

Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality.

A. D'Amico, P. Carroll, Ming-Hui Chen, 2006, Urology.

Association between preoperative erectile dysfunction and prostate cancer features--an analysis from the Duke Prostate Center Database.

J. Moul, S. Freedland, T. Polascik, 2012, The journal of sexual medicine.

The development of erectile dysfunction in men treated for prostate cancer.

J. Moul, W. Alvord, R. Costabile, 2001, The Journal of urology.

Long-term tolerability and efficacy of degarelix: 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix.

E. Crawford, J. Moul, K. Miller, 2014, Urology.

Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer

M. Gleave, J. Nelson, J. Moul, 2013, Prostate Cancer and Prostatic Diseases.

Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era.

Hongyu Wu, Judd W. Moul, David G. McLeod, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prostate specific antigen testing in men older than 75 years in the United States.

K. Schulman, J. Moul, D. Albala, 2006, The Journal of urology.

Cadmium-induced neoplastic transformation of human prostate epithelial cells.

J. Rhim, J. Moul, S. Srivastava, 2002, International journal of oncology.

PD08-10 SOCIAL MEDIA PRESENCE OF UNITED STATES ACADEMIC UROLOGY RESIDENCY PROGRAMS

J. Moul, A. Peterson, M. Ferrandino, 2019, Journal of Urology.

Molecular markers in prostate cancer: the role in preoperative staging.

J. Moul, S. Srivastava, A. Merseburger, 2002, Clinical prostate cancer.

FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist

L. Collette, E. Crawford, J. Moul, 2018, Scandinavian journal of urology.

1992 New York-Tidewater chapters History of Military Medicine Essay Award recipient. James Claude Kimbrough: the father of modern U.S. Army urology.

J. Moul, 1993, Military medicine.

Disparities in Prostate Cancer Screening for Transgender Women: An Analysis of the MarketScan Database.

J. Moul, C. Scales, Hui-Jie Lee, 2023, Urology.

Interrupted versus Continuous Suturing for Vesicourethral Anastomosis During Radical Prostatectomy: A Systematic Review and Meta-analysis.

J. Moul, F. Nickel, M. Kriegmair, 2019, European urology focus.

What the U.S. Preventive Services Task Force Missed in Its Prostate Cancer Screening Recommendation

Stephen W. Leslie, A. D'Amico, W. Catalona, 2012, Annals of Internal Medicine.

Inferior vena cava compression due to massive hydronephrosis from bladder outlet obstruction.

J. Moul, G. C. Davis, N. Aronson, 2000, Techniques in urology.

Role of oxidative stress in a rat model of radiation-induced erectile dysfunction.

J. Moul, T. Polascik, Hui Yan, 2012, The journal of sexual medicine.

M. Terris, A. Partin, J. Moul, 2007, JAMA.

Health policy: Health-care implications of resident duty-hour restrictions

J. Moul, C. Scales, S. Stewart, 2009, Nature Reviews Urology.

Downsides of robot-assisted laparoscopic radical prostatectomy: limitations and complications.

Markus Graefen, Rodolfo Montironi, Tullio Sulser, 2010, European urology.

COMPREHENSIVE PREOPERATIVE EVALUATION AND REPAIR OF INGUINAL HERNIAS AT THE TIME OF OPEN RADICAL RETROPUBIC PROSTATECTOMY DECREASES RISK OF DEVELOPING POSTPROSTATECTOMY HERNIA

J. Moul, 2012, BJU international.

Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras.

J. Moul, D. Albala, T. Polascik, 2009, The Journal of urology.

Improved prostate cancer-specific survival and other disease parameters: impact of prostate-specific antigen testing.

Laurence R. Paquette, J. Moul, R. Connelly, 2002, Urology.

Pharmacokinetic and pharmacodynamic comparison of subcutaneous versus intramuscular leuprolide acetate formulations in male subjects

E. Crawford, S. de la Motte, J. Moul, 2018, Therapeutic advances in urology.

Perirenal liposarcoma containing extramedullary hematopoiesis associated with renal cell carcinoma.

J. Moul, I. Sesterhenn, D. J. Lewis, 1994, Urology.

External beam radiation therapy after radical prostatectomy: efficacy and impact on urinary continence

J. Moul, R. Connelly, D. Mcleod, 2004, Prostate Cancer and Prostatic Diseases.

Gynaecomastia and extragonadal symptoms leading to diagnosis delay of germ cell tumours in young men.

J. Moul, 1991, Postgraduate medical journal.

Biostatistical modeling using traditional preoperative and pathological prognostic variables in the selection of men at high risk for disease recurrence after radical prostatectomy for prostate cancer.

J. Moul, S. Srivastava, J. Bauer, 1998, The Journal of urology.

Original article Predictors of extracapsular extension and positive margins in African American and White men

Laurence R. Paquette, J. Moul, R. Connelly, 2003 .

Teleconferencing as a Method of Educating Men About Managing Advanced Prostate Cancer and Pain

J. Moul, M. Glajchen, 1996 .

Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults.

Arash Naeim, Michel Bolla, John M. Fitzpatrick, 2010, Critical reviews in oncology/hematology.

Changing face and different countenances of prostate cancer: Racial and geographic differences in prostate‐specific antigen (PSA), stage, and grade trends in the PSA era

D. Brachman, R. Weichselbaum, J. Moul, 2001, International journal of cancer.

Will the global economic downturn affect prostate cancer care? Pelvic lymphadenectomy as an example.

J. Moul, 2009, European urology.

Implementation of a web-based prostate cancer decision site.

J. Moul, J. Bauer, T. A. Esther, 2000, Seminars in urologic oncology.

Reference ranges for serum prostate-specific antigen in black and white men without cancer.

J. Oesterling, J. Moul, M. Weinrich, 1998, Urology.

Re‐calibration and external validation of an existing nomogram to predict aggressive recurrences after radical prostatectomy

M. Terris, M. Kattan, J. Moul, 2009, BJU international.

RECALIBRATION AND EXTERNAL VALIDATION OF AN EXISTING NOMOGRAM TO PREDICT AGGRESSIVE RECURRENCES AFTER RADICAL PROSTATECTOMY (RP)

M. Terris, M. Kattan, J. Moul, 2009 .

NADiA ProsVue prostate-specific antigen slope is an independent prognostic marker for identifying men at reduced risk of clinical recurrence of prostate cancer after radical prostatectomy.

R. Vessella, J. Moul, H. Lilja, 2012, Urology.

Leuprolide acetate (once-yearly implant): profile report

J. Moul, D. Vaughn, 2012 .

Managing advanced prostate cancer with Viadur (leuprolide acetate implant).

J. Moul, K. Civitelli, 2001, Urologic nursing.

Identifying appropriate patients for early salvage radiotherapy after prostatectomy.

J. Moul, S. Freedland, M. Anscher, 2013, The Journal of urology.

Leuprolide Acetate

J. Moul, 2020, Definitions.

Hormonal therapy options for biochemical recurrence of prostate cancer after local therapy.

J. Moul, 2000, Molecular urology.

Optimized prostate biopsy via a statistical atlas of cancer spatial distribution

Dinggang Shen, Wei Zhang, Gabor Fichtinger, 2004, Medical Image Anal..

Optimization of prostate biopsy

Seong Ki Mun, Jianchao Zeng, John J. Bauer, 1999, Medical Imaging.

Activation of the PKB/Akt pathway in histological benign prostatic tissue adjacent to the primary malignant lesions.

J. Moul, M. Kuczyk, A. Stenzl, 2006, Oncology reports.

Prostate-specific antigen-based risk-adapted discontinuation of prostate cancer screening in elderly African American and Caucasian American men.

J. Moul, D. Albala, T. Polascik, 2010, Urology.

Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening.

J. Moul, D. Albala, P. Dahm, 2007, The Journal of urology.

Comparison of DRE and PSA in the Detection of Prostate Cancer.

J. Moul, Judd W Moul, 2017, The Journal of urology.

Biochemical recurrence after definitive prostate cancer therapy. Part I: Defining and localizing biochemical recurrence of prostate cancer*

J. Moul, J. Ward, 2005, Current opinion in urology.

Maximizing outcomes in genitourinary cancers across the treatment continuum

J. Moul, A. Zlotta, B. Tombal, 2011, BJU international.

Optimizing treatment for men with advanced prostate cancer: expert recommendations and the multidisciplinary approach.

J. Moul, C. Sternberg, V. Guillem, 2008, Critical reviews in oncology/hematology.

Prostate specific antigen recurrence after definitive therapy.

J. Moul, S. Freedland, 2007, The Journal of urology.

Management of the patient with a rising PSA alone.

J. Moul, J. Ward, 2006, Hematology/oncology clinics of North America.

Treating the biochemical recurrence of prostate cancer after definitive primary therapy.

J. Moul, J. Ward, 2005, Clinical prostate cancer.

Hormonal therapy options for prostate‐specific antigen‐only recurrence of prostate cancer after previous local therapy

J. Moul, A. Zlotta, 2005, BJU international.

670 SWITCHING FROM LEUPROLIDE TO DEGARELIX VS CONTINUOUS DEGARELIX TREATMENT – EFFECTS ON LONG-TERM PROSTATE-SPECIFIC ANTIGEN CONTROL

E. Crawford, J. Moul, N. Shore, 2010 .

Quality of Life Associated with Treatment of Castration-Resistant Prostate Cancer: A Review of the Literature

J. Moul, N. Dawson, 2012, Cancer investigation.

Over half of contemporary clinical Gleason 8 on prostate biopsy are downgraded at radical prostatectomy.

J. Moul, W. Foo, T. Longo, 2016, The Canadian journal of urology.

Most Gleason 8 Biopsies are Downgraded at Prostatectomy—Does 4 + 4 = 7?

A. Jemal, J. Moul, S. Fedewa, 2017, The Journal of urology.

Contemporary hormonal management of advanced prostate cancer.

J. Moul, 1998, Oncology.

Keeping an Open Mind About Novel Concepts for Management of Prostate Cancer.

J. Moul, T. Polascik, K. Tay, 2015, European urology.

Differences in self-reported outcomes of open prostatectomy patients and robotic prostatectomy patients in an international web-based survey.

J. Moul, C. Pinnock, A. Esterman, 2013, European journal of oncology nursing : the official journal of European Oncology Nursing Society.

Financial comparative analysis of minimally invasive surgery to open surgery for localized prostate cancer: a single-institution experience.

J. Moul, D. Albala, V. Mouraviev, 2007, Urology.

A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy

J. Moul, P. Tran, A. Armstrong, 2015, Prostate Cancer and Prostatic Disease.

Abstracts of the 15th Congress of the European Society for Urological Research, Istanbul, October 5–7, 2000

S. Loening, J. Moul, S. Srivastava, 2000, European Urology.

THE EPIDEMIOLOGY OF PROSTATE CANCER IN JAMAICA: EDITORIAL COMMENT

J. Moul, 1998 .

Novel techniques for the treatment of localized prostate cancer: Evidence of efficacy?

J. Moul, M. Robinson, 2007, Current urology reports.

Erectile function outcome reporting after clinically localized prostate cancer treatment.

Anthony V D'Amico, Javier Hernandez, S Larry Goldenberg, 2007, The Journal of urology.

Mature, clinical stage I testicular teratoma: retroperitoneal lymphadenetomy or surveillance?

F. Mostofi, J. Moul, I. Sesterhenn, 1997, Der Urologe.

Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure.

A. Renshaw, A. D'Amico, D. Lubeck, 2004, Journal of the National Cancer Institute.

Satisfaction and regret after open retropubic or robot-assisted laparoscopic radical prostatectomy.

J. Moul, D. Albala, T. Polascik, 2008, European urology.

Using the percentage of biopsy cores positive for cancer, pretreatment PSA, and highest biopsy Gleason sum to predict pathologic stage after radical prostatectomy: the Center for Prostate Disease Research nomograms.

J. Bishoff, J. Moul, C. Kane, 2003, Urology.

Race and prostate weight as independent predictors for biochemical recurrence after radical prostatectomy

J. Moul, S. Freedland, F. Schroeck, 2008, Prostate Cancer and Prostatic Diseases.

Sampling the spatial patterns of cancer: Optimized biopsy procedures for estimating prostate cancer volume and Gleason Score

Dinggang Shen, Christos Davatzikos, Yangming Ou, 2009, Medical Image Anal..

Salvage radiation in men after prostate‐specific antigen failure and the risk of death

A. D'Amico, Ming-Hui Chen, J. Moul, 2011, Cancer.

Will the future of health care lead to the end of the robotic golden years?

J. Moul, S. Reed, Suzanne Biehn Stewart, 2014, European urology.

Pretreatment expectations of patients undergoing robotic assisted laparoscopic or open retropubic radical prostatectomy.

J. Moul, D. Albala, F. Schroeck, 2012, The Journal of urology.

Cellular functions and pathways affected by PCGEM1, a prostate-specific gene associated with African-American prostate cancer patients

Wei Zhang, J. Moul, S. Srivastava, 2004 .

DOES PATHOLOGICAL GLEASON SCORE RE-REVIEW BY A MODERN PATHOLOGIST IMPROVE RISK STRATIFICATION RELATIVE TO HISTORICAL GLEASON SCORE?

J. Moul, S. Freedland, R. Vollmer, 2009 .

Prostate-specific antigen screening and prostate cancer mortality: implications of a randomized European study

J. Moul, C. Robertson, Leon L Sun, 2009 .

Utilization trends at a multidisciplinary prostate cancer clinic: initial 5-year experience from the Duke Prostate Center.

P. Febbo, J. Moul, S. Freedland, 2012, The Journal of urology.

Prostate cancer: an evolving paradigm.

J. Moul, V. Mouraviev, T. Polascik, 2010, Journal of endourology.

Bilateral organ-limited amyloidosis of the distal ureter associated with osseous metaplasia and radiographic calcification.

J. Moul, D. Mcleod, 1988, The Journal of urology.

Risk factors for perineal seeding of prostate cancer after needle biopsy.

J. Moul, B. Miles, D. Mcleod, 1989, The Journal of urology.

Retroperitoneal fibrosis following radiotherapy for stage I testicular seminoma.

J. Moul, 1992, The Journal of urology.

Prospective use of free prostate-specific antigen to avoid repeat prostate biopsies in men with elevated total prostate-specific antigen.

E. Leifer, J. Moul, G. Murphy, 1996, Urology.

Prospective use of free PSA to avoid repeat prostate biopsies in men with elevated total PSA

E. Leifer, J. Moul, G. Murphy, 1996, The Prostate. Supplement.

Prostate imaging based on rf spectrum analysis and nonlinear classifiers for guiding biopsies and targeting radiotherapy

Andrew Kalisz, Jeffrey A. Ketterling, Isabell A. Sesterhenn, 2001, SPIE Medical Imaging.

Masculinity Beliefs Predict Psychosocial Functioning in African American Prostate Cancer Survivors

L. Campbell, J. Moul, F. Keefe, 2012, American journal of men's health.

Preoperative Staging of Prostate Cancer: The Role of Molecular Markers

J. Moul, A. Merseburger, 2003 .

1184: How Long can Radical Prostatectomy (RP) Safely be Delayed? CPDR'S Experiences From 3324 Cases

Ken R. Smith, J. Moul, C. Amling, 2004 .

NCCN clinical practice guidelines in oncology: prostate cancer early detection.

Antoinette M Stroup, William J Catalona, James Mohler, 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

Characteristics of baseline PSA and PSA velocity in young men without prostate cancer: Racial differences

J. Moul, W. Du, P. Tang, 2012, The Prostate.

Long-term oncological outcomes of men undergoing radical prostatectomy with preoperative prostate-specific antigen <2.5 ng/ml and 2.5-4 ng/ml.

J. Moul, T. Polascik, L. Bañez, 2013, Urologic oncology.

Surrogate end point for prostate cancer specific mortality in patients with nonmetastatic hormone refractory prostate cancer.

A. D'Amico, D. Lubeck, P. Carroll, 2005, The Journal of urology.

Age‐Specific Reference Ranges for Prostate Specific Antigen in Young Men: Retrospective Study from the National Defense University

Joshua D. Hartzell, J. Moul, T. Kao, 2001 .

Impact of postoperative prostate‐specific antigen disease recurrence and the use of salvage therapy on the risk of death

A. D'Amico, Ming-Hui Chen, T. Choueiri, 2010, Cancer.

Impact of primary Gleason grade on risk stratification for Gleason score 7 prostate cancers.

J. Moul, V. Mouraviev, W. Lee, 2012, International journal of radiation oncology, biology, physics.

A single-institution comparison between radical perineal and radical retropubic prostatectomy on perioperative and pathological outcomes for obese men: an analysis of the Duke Prostate Center database.

J. Moul, S. Freedland, P. Dahm, 2007, Urology.

Risk of death from prostate cancer after radical prostatectomy or brachytherapy in men with low or intermediate risk disease.

A. D'Amico, Ming-Hui Chen, J. Moul, 2011, The Journal of urology.

Phase 1 trial of neoadjuvant radiation therapy before prostatectomy for high-risk prostate cancer.

J. Moul, M. Anscher, T. Polascik, 2013, International journal of radiation oncology, biology, physics.

The Shared Equal Access Regional Cancer Hospital (SEARCH) nomogram for risk stratification in intermediate risk group of men with prostate cancer: validation in the Duke Prostate Center database

J. Moul, S. Freedland, D. Moreira, 2010, BJU international.

Low central venous pressure versus acute normovolemic hemodilution versus conventional fluid management for reducing blood loss in radical retropubic prostatectomy: a randomized controlled trial

W. White, J. Moul, T. Polascik, 2014, Current medical research and opinion.

Prostate‐specific antigen velocity based risk‐adapted discontinuation of prostate cancer screening in elderly men

J. Moul, T. Polascik, C. Robertson, 2011, BJU international.

Utility of a 3-Dimensional Transrectal Ultrasound-guided Prostate Biopsy System for Prostate Cancer Detection

J. Moul, J. Madden, V. Mouraviev, 2009, Technology in cancer research & treatment.

A telomerase-immortalized primary human prostate cancer clonal cell line with neoplastic phenotypes.

J. Rhim, J. Moul, S. Srivastava, 2004, International journal of oncology.

Refusal of cancer therapy in testicular cancer: Recognizing and preventing a significant problem

J. Moul, D. Paulson, P. Walther, 1990, World Journal of Urology.

Pathological T2 sub‐divisions as a prognostic factor in the biochemical recurrence of prostate cancer

J. Moul, V. Mouraviev, T. Polascik, 2010, BJU international.

p63 expression profile in normal and malignant prostate epithelial cells.

Wei Zhang, J. Rhim, J. Moul, 2002, Anticancer Research.

Changes in Gleason score grading and their effect in predicting outcome after radical prostatectomy.

J. Moul, J. Madden, V. Mouraviev, 2009, Urology.

Yes or no to local therapy for oligometastatic prostate cancer?

J. Moul, 2018, Nature Reviews Urology.

DNA ploidy in nonseminomatous germ cell testicular tumor.

J. Moul, 1994, Urology.

Advances in Brief Percentage of Embryonal Carcinoma and of Vascular Invasion Predicts Pathological Stage in Clinical Stage I Nonseminomatous Testicular Cancer 1

J. Moul, I. Sesterhenn, W. Mccarthy, 2007 .

Unnecessary mastectomy for gynecomastia in testicular cancer patient.

J. Moul, J. R. Moellman, 1992, Military medicine.

Radical prostatectomy versus radiation therapy for clinically localized prostate carcinoma

J. Moul, 2002, Cancer.

Early prostate cancer: prevention, treatment modalities, and quality of life issues.

J. Moul, D. Penson, L. Klotz, 2003, European urology.

Use of serum creatinine to predict pathologic stage and recurrence among radical prostatectomy patients.

J W Moul, J. Moul, R. Connelly, 2001, Urology.

Obese African‐Americans with prostate cancer (T1c and a prostate‐specific antigen, PSA, level of <10 ng/mL) have higher‐risk pathological features and a greater risk of PSA recurrence than non‐African‐Americans

J. Moul, D. Albala, T. Polascik, 2010, BJU international.

OBESITY AS A PREDICTOR OF ADVERSE OUTCOME ACROSS BLACK AND WHITE RACE: RESULTS FROM THE SEARCH AND DUKE PROSTATE CENTER DATABASES

M. Terris, J. Moul, S. Freedland, 2008 .

441: Pathologic Variables and Recurrence Rates as Related to Obesity and Race in Men with Prostate Cancer Undergoing Radical Prostatectomy

J. Moul, C. Amling, W. Sexton, 2004 .

Clinical staging of prostate cancer: Reproducibility and clarification of issues

Srinivasan Vijayakumar, Alan Pollack, James Montie, 2001, International journal of cancer.

Baseline PSA as a predictor of prostate cancer‐specific mortality over the past 2 decades

J. Moul, S. Freedland, T. Polascik, 2010, Cancer.

African-American men with low-grade prostate cancer have higher tumor burdens: Results from the Duke Prostate Center

J. Moul, L. Gerber, L. Bañez, 2012, Prostate Cancer and Prostatic Diseases.

Prostate‐specific antigen 1.5–4.0 ng/mL: a diagnostic challenge and danger zone

J. Moul, C. Pettaway, K. Rove, 2011, BJU international.

Adjuvant versus salvage radiation therapy for prostate cancer and the risk of death

A. D'Amico, Ming-Hui Chen, J. Moul, 2010, BJU international.

Prostate-specific antigen versus prostate-specific antigen density as predictor of tumor volume, margin status, pathologic stage, and biochemical recurrence of prostate cancer.

J. Moul, T. Kao, S. Brassell, 2005, Urology.

The effect of race on the discriminatory accuracy of models to predict biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases

M. Terris, J. Moul, S. Freedland, 2010, Prostate Cancer and Prostatic Diseases.

A framework to evaluate the cost-effectiveness of the NADiA ProsVue slope to guide adjuvant radiotherapy among men with high-risk characteristics following prostatectomy for prostate cancer.

J. Moul, C. Scales, S. Reed, 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

When should we pull the trigger for post-radical prostatectomy radiotherapy?

J. Moul, 2012, European urology.

Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients

J. Moul, I. Sesterhenn, D. Mcleod, 1997, Cancer.

Use of local (111)in-capromab pendetide scan results to predict outcome after salvage radiotherapy for prostate cancer.

J. Moul, M. Anscher, V. Mouraviev, 2008, International journal of radiation oncology, biology, physics.

Prostate-specific antigen to predict outcome of external beam radiation for prostate cancer: Walter Reed Army Medical Center experience, 1988-1995.

E. Leifer, J. Moul, J. Bauer, 1999, Urology.

Preoperatiove prostate cancer volume estimation based on clinically correlated needle biopsy simulation

Wei Zhang, J. Moul, S. Mun, 2002 .

Trainees do not negatively impact the institutional learning curve for robotic prostatectomy as characterized by operative time, estimated blood loss, and positive surgical margin rate.

J. Moul, D. Albala, S. Pierre, 2008, Urology.

Prostate-specific antigen-enhanced testing and risk stratification for chemoprevention trials.

J. Moul, 2001, Urology.

Prostate-specific antigen (PSA) progression-free survival (PFS): A comparison of degarelix versus leuprolide in patients with prostate cancer.

E. Crawford, J. Moul, N. Shore, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

866 PROSTATE-SPECIFIC ANTIGEN AND SERUM ALKALINE PHOSPHATASE LEVELS IN PROSTATE CANCER PATIENTS RECEIVING DEGARELIX OR LEUPROLIDE

E. Crawford, J. Moul, N. Shore, 2010 .

Prostate cancer: diagnosis, treatment, and experience at one tertiary-care military medical center, 1989 and 1994.

J. Moul, J. Bauer, D. Mcleod, 1996, Military medicine.

Statistical modeling using preoperative prognostic variables in predicting extracapsular extension and progression after radical prostatectomy for prostate cancer.

J. Moul, J. Bauer, R. Connelly, 1998, Military medicine.

Prostate cancer: the new landscape

J. Moul, V. Mouraviev, T. Polascik, 2009, Current opinion in urology.

Prostate‐specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years

J. Moul, D. Albala, T. Polascik, 2007, BJU international.

Robot‐assisted laparoscopic prostatectomy is not associated with early postoperative radiation therapy

J. Moul, D. Albala, W. Lee, 2009, BJU international.

Comparison of prostate‐specific antigen recurrence‐free survival in a contemporary cohort of patients undergoing either radical retropubic or robot‐assisted laparoscopic radical prostatectomy

J. Moul, S. Freedland, V. Mouraviev, 2008, BJU international.

The role of early adopter bias for new technologies in robot assisted laparoscopic prostatectomy.

J. Moul, D. Albala, P. Dahm, 2007, The Journal of urology.

Hot topic of cancer survivorship and the ‘seven deadly sins’

J. Moul, 2015, BJU international.

Thymic hyperplasia in newly diagnosed testicular germ cell tumors.

J. Moul, D. Mcleod, C. K. Ho, 1994, The Journal of urology.

Rising PSA after local therapy failure: immediate vs deferred treatment.

J. Moul, 1999, Oncology.

Evaluation of cathepsin D and epidermal growth factor receptor in prostate carcinoma.

J. Moul, S. Maygarden, J. Ware, 1994, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

How I Use It: The Exosome Diagnostics (EPI) prostate cancer biomarker utility in urology and primary care.

J. Moul, G. Sant, 2022, The Canadian journal of urology.

Methylation of TFPI-2 gene is not the sole cause of its silencing.

J. Moul, S. Srivastava, C. N. Rao, 2003, International journal of oncology.

A multidisciplinary opioid-reduction pathway for robotic prostatectomy: outcomes at year one

Timothy C. Miller, J. Moul, Erin L. Manning, 2023, Perioperative Medicine.

Conservative Management of a Pyelovenous Fistula After a Renal Gunshot Wound

J. Moul, Michael Stern, Neel H Patel, 2019, Journal of endourology case reports.

Editorial comment.

J. Moul, 2010, Urology.

Pelvic muscle rehabilitation in males following prostatectomy.

J. Moul, 1998, Urologic nursing.

Rupture of the deep dorsal vein of the penis during sexual intercourse.

J. Moul, R. Costabile, E. Nicely, 1992, The Journal of urology.

Perspective on Expanding Androgen-Targeted Treatments for Men With Castration-Resistant Prostate Cancer

J. Moul, 2014 .

Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature.

A. D'Amico, M. Cooperberg, H. Scher, 2013, European urology.

Public survey and survival data do not support recommendations to discontinue prostate-specific antigen screening in men at age 75.

J. Moul, D. Albala, T. Polascik, 2010, Urology.

Baseline Prostate-Specific Antigen Testing at a Young Age

W. Catalona, J. Moul, H. Carter, 2012 .

Prostate cancer: Active surveillance in African American men

J. Moul, 2013, Nature Reviews Urology.

Should elderly men be screened for prostate cancer

J. Moul, V. Mouraviev, 2008 .

Commentary (Moul): Prostate Cancer Risk Assessment Program

J. Moul, 1999 .

EDITORIAL: PROSTATE CANCER 1997-PRACTICING WHAT WE PREACH

J. Moul, 1997 .

Patient selection for experimental adjuvant therapy after radical prostatectomy.

J. Moul, W. Mccarthy, D. Mcleod, 1996, Urology.

Radical prostatectomy and cryotherapy--some answers, more questions.

J. Moul, 1997, Journal of Urology.

Prostate cancer early detection

John T. Wei, P. Carroll, Ruth Etzioni, 2010 .

An important goal of prostatectomy: minimizing incontinence.

J. Moul, 1994, Contemporary urology.

Epidemiology and screening for prostate cancer.

J. Moul, 1997, The American journal of managed care.

Distribution of Prostrate Cancer for Optimized Biopsy Protocols

Wei Zhang, Ariela Sofer, Seong Ki Mun, 2000, MICCAI.

Building an accurate 3D map of prostate cancer using computerized models of 280 whole-mounted radical prostatectomy specimens

Seong Ki Mun, Jianchao Zeng, John J. Bauer, 2000, Medical Imaging.

Visualization and Evaluation of Prostrate Needle Biopsy

Seong Ki Mun, Jianchao Zeng, Charles Kaplan, 1998, MICCAI.

3D model supported virtual environment for prostate disease interpretation and biopsy design

Jianhua Xuan, J. Moul, S. Mun, 1998, Proceedings Pacific Medical Technology Symposium-PACMEDTek. Transcending Time, Distance and Structural Barriers (Cat. No.98EX211).

Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification

K. Pienta, J. Moul, S. Freedland, 2023, Prostate cancer and prostatic diseases.

Does variation in either age at start of therapy or duration of therapy make chemoprevention with finasteride cost-effective?

J. Moul, J. Moul, C. Scales, 2011, Prostate Cancer and Prostatic Diseases.

Transdermal Nicotine for Analgesia After Radical Retropubic Prostatectomy

W. White, J. Moul, T. Polascik, 2008, Anesthesia and analgesia.

Satisfaction and regret after open retropubic or robot-assisted laparoscopic radical prostatectomy.

J. Moul, D. Albala, T. Polascik, 2008, European urology.

Optimizing treatment for men with advanced prostate cancer: expert recommendations and the multidisciplinary approach.

J. Moul, C. Sternberg, V. Guillem, 2008, Critical reviews in oncology/hematology.

A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer.

J. Moul, K. Miller, B. Tombal, 2011, The Journal of urology.